The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine…

Go here to discover the crypto that's about to leave Wall Street in the dust.

Jennifer B. Damico net worth and biography

Jennifer Damico Biography and Net Worth

SVP of Pfizer

Jennifer Damico is Vice President, Corporate Audit, Pfizer Inc, reporting to the Audit Committee of the Board of Directors and the Chief Financial Officer. She is responsible for leading 100 audit professionals primarily based in New York, New Jersey, Connecticut, Pennsylvania, Mumbai, Dublin and Beijing. Corporate Audit provides independent, Pan-Pfizer corporate regulatory audit and oversight of processes and systems spanning the company's operating model including: discovery, development, manufacturing, commercial sales & marketing activities, finance and information technology.

Jennifer joined Pfizer in 1992 and has held positions of increasing responsibility in Audit, Information Technology, and Finance. She joined the company as a Senior Internal Auditor and was promoted to Audit Manager in 1994. In 1997, Jennifer joined the Corporate Information Technology Division as Director of Finance and Controller. In 2001, she rejoined Internal Audit as an Audit Director and was promoted to Senior Director, Strategy, Governance and Operations in 2008. Jennifer served as the Program Management Office (PMO) Lead for the Finance One transformation program and led the finance integration for the King acquisition. In 2010, she became Vice President, Finance Portfolio Management & Optimization, and established a new organization to provide centralized, customer-focused project & change management as well as coordination of finance integration and divestiture activities which more recently included supporting the Nutritional and Animal Health divestitures. Prior to joining Pfizer, she worked as a senior auditor for Arthur Andersen.

Jennifer holds a Master of Business Administration degree from Pace University and is a Certified Public Accountant. She is married with two children Ryan, 15 and Courtney, 13 and lives in Long Island, NY.

What is Jennifer B. Damico's net worth?: The estimated net worth of Jennifer B. Damico is at least $309,978.68 as of June 7th, 2022. Ms. Damico owns 10,846 shares of Pfizer stock worth more than $309,979 as of October 5th. This net worth approximation does not reflect any other investments that Ms. Damico may own. Learn More about Jennifer B. Damico's net worth.
How old is Jennifer B. Damico?: Ms. Damico is currently 56 years old. There are 7 older executives and no younger executives at Pfizer. The oldest executive at Pfizer is Dr. Mikael Dolsten M.D., Ph.D., Chief Scientific Officer and President of Research & Development, who is 66 years old. Learn More on Jennifer B. Damico's age.
How do I contact Jennifer B. Damico?: The corporate mailing address for Ms. Damico and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Jennifer B. Damico's contact information.
Has Jennifer B. Damico been buying or selling shares of Pfizer?: Jennifer B. Damico has not been actively trading shares of Pfizer within the last three months. Most recently, Jennifer B. Damico sold 4,218 shares of the business's stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a transaction totalling $227,603.28. Following the completion of the sale, the senior vice president now directly owns 10,846 shares of the company's stock, valued at $585,250.16. Learn More on Jennifer B. Damico's trading history.
Who are Pfizer's active insiders?: Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.
Are insiders buying or selling shares of Pfizer?: In the last year, Pfizer insiders bought shares 1 times. They purchased a total of 3,000 shares worth more than $79,410.00. The most recent insider tranaction occured on December, 15th when Director Scott Gottlieb bought 3,000 shares worth more than $79,410.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.
Information on this page was last updated on 12/15/2023.

Jennifer B. Damico Insider Trading History at Pfizer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/7/2022	Sell	4,218	$53.96	$227,603.28	10,846
5/16/2022	Sell	4,000	$50.50	$202,000.00	15,064
8/13/2021	Sell	1,661	$48.30	$80,226.30
7/30/2021	Sell	2,500	$42.86	$107,150.00	11,430
5/5/2021	Sell	2,500	$40.82	$102,050.00	13,748
6/5/2020	Sell	2,181	$36.13	$78,799.53	7,542
4/29/2020	Sell	2,181	$38.35	$83,641.35	9,647

Jennifer B. Damico Buying and Selling Activity at Pfizer

Pfizer Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Today's Range

Now: $28.58

$28.24

$28.59

50 Day Range

MA: $29.17

$28.29

$31.38

2 Week Range

Now: $28.58

$25.20

$33.92

Volume

28,786,884 shs

Average Volume

37,384,395 shs

Market Capitalization

$161.95 billion

P/E Ratio

N/A

Dividend Yield

5.81%

Beta

0.67

Next opportunity for crypto millions

From Crypto 101 Media | Ad